Hytrin: Effective Blood Pressure and Prostate Symptom Control
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.96 | $57.56 (0%) | 🛒 Add to cart |
| 90 | $0.86 | $86.34 $77.75 (10%) | 🛒 Add to cart |
| 120 | $0.82 | $115.12 $98.96 (14%) | 🛒 Add to cart |
| 180 | $0.77 | $172.67 $138.34 (20%) | 🛒 Add to cart |
| 270 | $0.74 | $259.01 $199.94 (23%) | 🛒 Add to cart |
| 360 | $0.73
Best per pill | $345.35 $262.54 (24%) | 🛒 Add to cart |
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.46 | $73.71 (0%) | 🛒 Add to cart |
| 60 | $1.92 | $147.43 $115.12 (22%) | 🛒 Add to cart |
| 90 | $1.74 | $221.14 $156.52 (29%) | 🛒 Add to cart |
| 120 | $1.65 | $294.86 $197.92 (33%) | 🛒 Add to cart |
| 180 | $1.56 | $442.28 $280.72 (37%) | 🛒 Add to cart |
| 270 | $1.51
Best per pill | $663.43 $406.94 (39%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.00 | $89.87 (0%) | 🛒 Add to cart |
| 60 | $2.26 | $179.74 $135.31 (25%) | 🛒 Add to cart |
| 90 | $2.01 | $269.61 $180.75 (33%) | 🛒 Add to cart |
| 120 | $1.89 | $359.48 $227.20 (37%) | 🛒 Add to cart |
| 180 | $1.77 | $539.22 $318.08 (41%) | 🛒 Add to cart |
| 270 | $1.69
Best per pill | $808.84 $455.41 (44%) | 🛒 Add to cart |
Synonyms
| |||
Hytrin (terazosin hydrochloride) is an alpha-1 adrenergic blocker prescription medication designed to manage hypertension and benign prostatic hyperplasia (BPH). By selectively relaxing vascular and prostate smooth muscle, it facilitates easier blood flow and improved urinary function. This long-acting formulation offers consistent 24-hour control with once-daily dosing, making it a cornerstone in cardiovascular and urological therapeutic regimens. Clinical evidence supports its efficacy in reducing both systolic and diastolic pressures while alleviating obstructive and irritative urinary symptoms associated with prostate enlargement.
Features
- Active ingredient: Terazosin hydrochloride
- Available in tablet strengths: 1 mg, 2 mg, 5 mg, 10 mg
- Mechanism: Selective blockade of postsynaptic alpha-1 adrenergic receptors
- Administration: Oral, once daily
- Half-life: Approximately 12 hours
- Bioavailability: ~90% following oral administration
- Excretion: Primarily fecal (60%) and renal (40%)
Benefits
- Effectively lowers both systolic and diastolic blood pressure, reducing cardiovascular risk
- Significantly improves urinary flow rates and reduces residual urine volume in BPH
- Decreases frequency and urgency of urination, providing symptomatic relief
- Once-daily dosing supports medication adherence and steady-state plasma concentrations
- May improve quality of life through better blood pressure control and reduced urinary symptoms
- Can be used as monotherapy or in combination with other antihypertensive agents
Common use
Hytrin is primarily indicated for the management of mild to moderate hypertension, either as monotherapy or in combination with other antihypertensive drugs such as diuretics or beta-blockers. In urology, it is prescribed for the symptomatic treatment of benign prostatic hyperplasia to improve urinary flow and reduce symptoms of obstruction. Physicians may also consider off-label uses in certain cases of renal hypertension or pheochromocytoma management under specialist supervision.
Dosage and direction
For hypertension: Initial dose is 1 mg at bedtime. Dosage may be gradually increased to achieve desired blood pressure response, typically up to 20 mg daily. Maximum recommended dose is 20 mg/day. For BPH: Initial dose is 1 mg at bedtime, gradually titrated upward to 5-10 mg daily based on symptom response and tolerability. Patients should be advised to take the first dose at bedtime due to potential first-dose hypotension. Tablets should be swallowed whole with water, with or without food, though consistent administration relative to meals is recommended.
Precautions
Patients should be monitored for orthostatic hypotension, particularly during initial titration. Caution is advised when rising from sitting or lying positions. Use with caution in patients with renal impairment, hepatic dysfunction, or history of gastrointestinal narrowing. Regular ophthalmic examinations are recommended during long-term therapy. Patients should inform healthcare providers about all medications being taken. Blood pressure should be monitored regularly during therapy. Not recommended during pregnancy unless potential benefits outweigh risks.
Contraindications
Hypersensitivity to terazosin or any component of the formulation. Concurrent use with other alpha-adrenergic blocking agents. Patients with a history of orthostatic hypotension. Severe hepatic impairment. Not indicated for use in pediatric patients. Should not be used in patients with demonstrated hypersensitivity to quinazolines.
Possible side effect
Common: Dizziness (19%), asthenia (11%), nasal congestion (6%), peripheral edema (5%), somnolence (5%), nausea (4%) Less common: Palpitations, blurred vision, impotence, weight gain, urinary frequency Rare: Syncope, priapism, allergic reactions including rash and urticaria First-dose effect: Significant hypotension with syncope may occur within 30-90 minutes of initial dose
Drug interaction
Enhanced hypotensive effects with other antihypertensive agents, nitrates, phosphodiesterase-5 inhibitors. NSAIDs may decrease antihypertensive effect. Caution with concomitant use of erectile dysfunction medications. Potential interaction with beta-blockers and calcium channel blockers requiring dosage adjustment. Monitor with CYP3A4 inhibitors/inducers.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for a missed dose. If multiple doses are missed, contact healthcare provider for guidance on retitration. Maintain regular dosing schedule to ensure consistent therapeutic effect.
Overdose
Symptoms may include severe hypotension, dizziness, lightheadedness, and syncope. Supportive care including supine positioning and volume expansion with intravenous fluids is primary treatment. Vasopressors may be required for persistent hypotension. Gastric lavage may be considered if ingestion was recent. Dialysis is not likely to be effective due to high protein binding.
Storage
Store at controlled room temperature 20-25°C (68-77°F). Protect from light and moisture. Keep in original container with lid tightly closed. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Do not transfer to other containers as this may affect stability.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment decisions. Individual response to medication may vary. Do not start, stop, or change dosage without medical supervision. Full prescribing information should be reviewed before initiation of therapy.
Reviews
Clinical studies demonstrate Hytrin’s efficacy in reducing blood pressure by 10-15 mmHg systolic and 5-10 mmHg diastolic. In BPH trials, peak urinary flow rates improved by 30-40% with significant symptom score reduction. Patient satisfaction surveys indicate improved quality of life measures related to both cardiovascular and urinary symptoms. Long-term safety data support sustained efficacy with maintained tolerability profile over years of therapy.